Holen Sie sich die Stockscreener-App
160.79
0.19%
-0.31
Schlusskurs vom Vortag:
$161.10
Offen:
$162.53
24-Stunden-Volumen:
3.15M
Relative Volume:
1.28
Marktkapitalisierung:
$303.67B
Einnahmen:
$54.66B
Nettoeinkommen (Verlust:
$13.58B
KGV:
22.91
EPS:
7.0171
Netto-Cashflow:
$16.05B
1W Leistung:
+6.40%
1M Leistung:
+12.78%
6M Leistung:
+8.75%
1J Leistung:
+31.14%
1-Tages-Spanne:
$160.40
$164.06
1-Wochen-Bereich:
$152.02
$164.06
52-Wochen-Spanne:
$121.98
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
160.79 | 303.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,417.54 | 1.26T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.20 | 657.68B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
294.89 | 521.11B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
149.52 | 368.89B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-10 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2026-09-09 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2026-09-09 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-03-11 | Hochstufung | Argus | Hold → Buy |
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2026-01-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-12-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-09-12 | Herabstufung | Goldman | Neutral → Sell |
| 2025-08-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Herabstufung | UBS | Buy → Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2025-02-04 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-09-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-09-03 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-19 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-09-25 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-26 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-05 | Hochstufung | Stifel | Hold → Buy |
| 2022-09-15 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-05-09 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Fortgesetzt | Citigroup | Buy |
| 2021-12-14 | Herabstufung | Redburn | Buy → Neutral |
| 2021-12-06 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Eingeleitet | Bernstein | Mkt Perform |
| 2021-03-10 | Herabstufung | Argus | Buy → Hold |
| 2021-02-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2020-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-03-10 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-04-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-04-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2018-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Bestätigt | Leerink Partners | Outperform |
| 2017-12-06 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Eingeleitet | Liberum | Buy |
Alle ansehen
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Novartis AG (NVS) Seasonal returns chart - Yahoo Finance UK
Novartis AG (NVS) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 79/100 - GuruFocus
China Upends Global Drug Development With Cheap and Rapid Human Trials - Bloomberg.com
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised - Zacks Investment Research
Should You Buy Royalty Pharma Stock Before Nov. 4? - The Motley Fool
Novartis AG (NVS) Stock Forecasts - Yahoo! Finance Canada
Novartis AG : Bernstein reiterates its Neutral rating - www.marketscreener.com
Novartis AG : JP Morgan reiterates its Buy rating - marketscreener.com
Novartis AG Stock 12‑Month Price Target Raised to $158.2, Implies 1% Upside - TradingView
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie - Zacks Investment Research
Novartis AG (NVS) Stock Forecasts - Yahoo Finance
What Novartis (NVS) Said on Its Q3 Earnings Call - Yahoo Finance
Novartis AG (NVS) (Q3 2026) Earnings Call Highlights: Raised Gui - GuruFocus
Novartis AG (NVS) (Q3 2026) Earnings Call Highlights: Raised Guidance and Priority Brand ... - Yahoo Finance
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9B Avidity HitNovartis (NYSE:NVS) - Benzinga
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential - Zacks Investment Research
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss - Zacks Investment Research
Novartis takes $1.9bn writedown on key drug after blockbuster Avidity acquisition - Financial Times
NOVARTIS AG N (NOTA.DU) Q3 FY2026 earnings call transcript - Yahoo Finance
The Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREP - Yahoo Finance
Novartis Raises Outlook on Growth of New Medicines - Bloomberg.com
Novartis lifts profit outlook as new medicines counter generic erosion (NVS:NYSE) - Seeking Alpha
Novartis reports Q3 core EPS $2.46 vs. $2.25 last year - TipRanks
Novartis AG reports results for the quarter ended September 30Earnings Summary - TradingView
Novartis Q3 Core Earnings, Net Sales Increase; 2026 Net Sales Growth Outlook Maintained - Yahoo Finance
Novartis: Q3 Earnings Snapshot - Yahoo Finance
Top Analyst Reports for Intel, Novartis & Itau Unibanco - Zacks Investment Research
Earnings To Watch: Novartis AG (XSWX:NOVN) Q3 2026 -- GF Value Sees 8% Downside - Yahoo Finance
Novartis AG : UBS sticks Neutral - marketscreener.com
Novartis MS Pill Trials Trigger Analyst Skepticism on Peak Sales - Bloomberg.com
Novartis AG : Gets a Neutral rating from RBC - marketscreener.com
Novartis AG : Gets a Neutral rating from Barclays - marketscreener.com
Novartis: Strong Drug Growth Faces A Tougher Test As Patent Losses And Pipeline Setbacks Mount - Seeking Alpha
Novartis Reports Positive Results from Late-stage Studies for Remibrutinib - marketscreener.com
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity - Yahoo Finance
Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple SclerosisSlideshow - Seeking Alpha
Novartis AG Remibrutinib in MS Investor Call Transcript - GuruFocus
Novartis AG (NVS) Stock Down 3.3% but Still Overvalued -- GF Score: 75/100 - GuruFocus
Novartis AG : RBC is Neutral - marketscreener.com
Novartis Multiple Sclerosis Pill Missed Expectations in Key Study - Bloomberg.com
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib - Reuters
Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study - Bloomberg.com
Novartis AG Stock (NVS) Moved Down by 3.61% on Oct 23: Facts Behind the Movement - TradingKey
Novartis AG Estimates – BX:NOT - TradingView
Novartis AG expected to post earnings of $2.29 a shareEarnings Preview - TradingView
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research
Novartis AG Lobbying Profile, 2004 - OpenSecrets
Earnings Preview: Novartis AG to Report Financial Results on October 27 - Moomoo
Finanzdaten der Novartis Ag Adr-Aktie (NVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Novartis Ag Adr-Aktie (NVS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bulto Carulla Victor | Officer |
Apr 30 '26 |
Proposed Sale |
148.10 |
6,800 |
1,007,093 |
0 |
| Marshall Fiona | Officer |
Feb 12 '26 |
Proposed Sale |
161.35 |
30,743 |
4,960,277 |
0 |
| Bulto Carulla Victor | Officer |
Feb 09 '26 |
Proposed Sale |
156.21 |
7,500 |
1,171,576 |
0 |
7.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):